Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G. Willett, Yves Boucher, Emmanuelle di Tomaso et al.|Nature Medicine|2004Cited by 2k
Design and Endpoints of Clinical Trials in Hepatocellular CarcinomaJosep M. Llovet, Gregory J. Gores, Adrian M. Di Bisceglie et al.|JNCI Journal of the National Cancer Institute|2008Cited by 1.7k
Biology and significance of alpha‐fetoprotein in hepatocellular carcinomaPeter R. Galle, Andrew X. Zhu, Friedrich Foerster et al.|Liver International|2019Cited by 591
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of SorafenibAndrew X. Zhu, Li‐Tzong Chen, Masatoshi Kudo et al.|JAMA|2014Cited by 569
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive CholangiocarcinomaLipika Goyal, Andrew X. Zhu|Cancer Discovery|2016Cited by 539